Human Plasma-derived Therapeutics Obtained with PPPS™ Technology
The collection of plasma and generation of plasma-derived therapeutics are expensive activities. The industry needs and requires innovative technologies and turnkey manufacturing processes that allow for maximum extraction, recovery and purification returns from a partner with globally recognized expertise in the field.
Prometic exploits a proprietary platform derived from the use of its UK based subsidiary (Prometic BioSciences Ltd.) affinity technology while Prometic’s US based subsidiary (Prometic BioTherapeutics) is responsible for the development and commercialization of the plasma purification process designated as Plasma Protein Purification System (“PPPSTM”).
PPPSTM is a multi- product sequential purification process originally developed in collaboration with the American Red Cross. It employs powerful affinity separation materials in a multi-step process to extract and purify commercially valuable plasma proteins in high yields. It allows for a highly efficient extraction and purification of multiple high-value therapeutic proteins from a single human plasma sample at unprecedented activity levels using Prometic’s MimeticTM Ligand adsorbent technology in order to develop best in class biotherapeutic products.
At the heart of our PPPSTM purification process is an application of our core MimeticTM Ligand bioseparation technologies which are used in a variety of applications from the production and purification of biopharmaceuticals, to the capture and removal of biocontaminants or extraction and recovery of valuable proteins from various sources. This affinity chromatography technique uses an adsorbent comprised of a porous support matrix to which the ligand is attached. The attachment or bonding is performed so that the immobilized ligand is still able to interact with the protein in a specific and reversible manner. The ligand is normally bound by the protein at a specific site often within a fold of the protein.
Prometic’s state of the art technologies and products are embedded into a successfully scaled-up manufacturing process for the development, manufacturing and commercialization of best in class plasma-derived therapeutics. Prometic’s proprietary and proven affinity adsorbents are incorporated in a downstream, multi-sequential chromatographic process to extract, isolate and purify high-value proteins with superior yield and efficiency from what is currently available from the industry. The process also incorporates viral inactivation as well as prion reduction that surpass the industry alcohol based extraction process. The gentle process provides for significantly better yield and economic benefits and is easily adaptable to different protein market needs.
Prometic’s technology provides for enhanced yield, safety and purity of blood plasma derived products compared to industry standards.